Printer Friendly

Extraction and Exploration of a Novel Selective Kappa Opioid Ligand.

Salvinorin A is a neoclerodane diterpene and is the active component in plant, Salvia divinorum. This compound has been shown to be a potent kappa opioid agonist in vitro and in vivo. At this moment, salvinorin A is the only known naturally occurring nonnitrogenous kappa opioid selective ligand. Its selectivity and activity at the kappa opioid receptor makes it a possible novel treatment for substance abuse. This is because kappa opioid agonists have been shown to antagonize the effects of central nervous stimulants by regulating the effect of dopamine in the brain; thereby, diminishing the stimulating effects of cocaine. In addition, kappa opioid agonists also have analgesic properties, so salvinorin A could also be a potential analgesia. As part of our ongoing research, we have successfully optimized a procedure to extract salvinorin A from the leaves of Salvia divinorum; we are also exploring analogues of Salvinorin A using structure-activity relationship studies.

Prisinzano, T.E., W. Harding, K. Tidgewell and * N. Echebiri. College of Pharmacy, Medicinal Natural Product Chemistry Department, University of Iowa and Department of Agriculture and Natural Sciences, Lincoln University.
COPYRIGHT 2005 Missouri Academy of Science
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Chemistry, Collegiate Division
Author:Gordon, James
Publication:Transactions of the Missouri Academy of Science
Date:Jan 1, 2005
Words:181
Previous Article:A "green" synthesis intended for undergraduate organic students.
Next Article:Heat energy and mass balance determination for the combustion of potassium nitrate based model rocket fuels.


Related Articles
Superheated water offers alternative for plant extractions.
Design, Synthesis and Complexation Characteristics of a Simple Dipyridyl Ligand. (Chemistry Section).
GENEFORMATICS/DE NOVO FORM DRUG DISCOVERY COLLABORATION.
GRAFFINITY SIGNS COLLABORATION AGREEMENT WITH ELI LILLY.
Maruho, Toray to Co-develop Antipruritic Agent for Dialysis Patients.
Chemistry and chemical engineering.
Toray, JT, Torii to Co-Develop, Market TRK-820 Antipruritus Drug for Hepatic Disease Patients in Japan.
Toray Files New Drug Application of TRK-820 Antipruritic Agent, Treatment of Severe Pruritus in Hemodialysis Patients in Japan.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters